Literature DB >> 15157522

Chemical inhibitors of cyclin-dependent kinases.

L Meijer1.   

Abstract

Transient activation o f cyclin-dependent kinases (CDKs) is responsible for transition through the successive phases of the cell-division cycle. Major changes in the expression and regulation of CDKs have been described in human tumours. Enzymatic screening is starting to uncover chemical inhibitors o f CDKs that arrest the cell cycle at various steps. This review summarizes our knowledge of the first generation inhibitors, their molecular mechanisms of action and their effects on the cell cycle and apoptosis, and discusses their potential as synchronizing agents, as ligands for affinity chromatography and as therapeutic agents.

Entities:  

Year:  1996        PMID: 15157522     DOI: 10.1016/0962-8924(96)10034-9

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  32 in total

1.  BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site.

Authors:  H Ruffner; W Jiang; A G Craig; T Hunter; I M Verma
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

Review 2.  Anticancer drug targets: cell cycle and checkpoint control.

Authors:  G I Shapiro; J W Harper
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

3.  Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1).

Authors:  K Hiromura; J W Pippin; M L Fero; J M Roberts; S J Shankland
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

Review 4.  Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine.

Authors:  Gerhard Eisenbrand; Frankie Hippe; Sandra Jakobs; Stephan Muehlbeyer
Journal:  J Cancer Res Clin Oncol       Date:  2004-08-31       Impact factor: 4.553

5.  Inactivation of Cdk1/Cyclin B in metaphase-arrested mouse FT210 cells induces exit from mitosis without chromosome segregation or cytokinesis and allows passage through another cell cycle.

Authors:  James R Paulson
Journal:  Chromosoma       Date:  2007-01-26       Impact factor: 4.316

6.  Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27.

Authors:  J Vlach; S Hennecke; B Amati
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

7.  A chemical compound commonly used to inhibit PKR, {8-(imidazol-4-ylmethylene)-6H-azolidino[5,4-g] benzothiazol-7-one}, protects neurons by inhibiting cyclin-dependent kinase.

Authors:  Hsin-Mei Chen; Lulu Wang; Santosh R D'Mello
Journal:  Eur J Neurosci       Date:  2008-11       Impact factor: 3.386

8.  Cdc6 protein causes premature entry into S phase in a mammalian cell-free system.

Authors:  K Stoeber; A D Mills; Y Kubota; T Krude; P Romanowski; K Marheineke; R A Laskey; G H Williams
Journal:  EMBO J       Date:  1998-12-15       Impact factor: 11.598

Review 9.  Selectivity and potency of cyclin-dependent kinase inhibitors.

Authors:  Jayalakshmi Sridhar; Nagaraju Akula; Nagarajan Pattabiraman
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

10.  Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases.

Authors:  L M Schang; A Rosenberg; P A Schaffer
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.